{"id":28617,"date":"2023-10-18T11:56:50","date_gmt":"2023-10-18T10:56:50","guid":{"rendered":"https:\/\/breastcancer.knowledgehub.wiley.com\/articoli\/potenziale-cinico-degli-inibitori-delle-cdk4-6-nel-tumore-del-senoprof-giuseppe-curigliano\/"},"modified":"2024-01-22T14:57:27","modified_gmt":"2024-01-22T14:57:27","slug":"caso-di-studio-giuseppe-curigliano","status":"publish","type":"post","link":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/","title":{"rendered":"Potenziale cinico degli inibitori delle CDK4\/6 nel tumore del seno<br><small>Prof. Giuseppe Curigliano<\/small>"},"content":{"rendered":"\n\n\t<p>In questo caso di studio, il Prof. Giuseppe Curigliano discute il potenziale clinico degli inibitori delle CDK4\/6 nel tumore del seno.<\/p>\n  <style>\n  video-js.video-js.vjs-fluid:not(.vjs-audio-only-mode) {\n    padding-top: 56.25%;\n  }\n  <\/style><video-js\n    data-account=\"656326989001\"\n    data-player=\"OQw83zhdgh\"\n    data-embed=\"default\"\n    controls=\"\"\n    data-video-id=\"6339385615112\"\n    data-playlist-id=\"\"\n    data-application-id=\"\"><\/video-js>\n\t<h3>Rispondi al Quiz sul caso di studio:<\/h3>\n<script>\n                            if (window.qmn_quiz_data === undefined) {\n                                    window.qmn_quiz_data = new Object();\n                            }\n                    <\/script><script>window.qmn_quiz_data[\"1\"] = {\"quiz_id\":\"1\",\"quiz_name\":\"Giuseppe Curigliano - Clinical potential of CDK4\\\/6 inhibitors in Breast Cancer\",\"disable_answer\":0,\"ajax_show_correct\":0,\"progress_bar\":\"0\",\"contact_info_location\":0,\"qpages\":{\"1\":{\"id\":\"1\",\"quizID\":\"1\",\"pagekey\":\"CCzuw6Fr\",\"hide_prevbtn\":\"0\"}},\"skip_validation_time_expire\":0,\"timer_limit_val\":\"0\",\"disable_scroll_next_previous_click\":0,\"disable_scroll_on_result\":0,\"disable_first_page\":\"0\",\"enable_result_after_timer_end\":0,\"enable_quick_result_mc\":0,\"end_quiz_if_wrong\":0,\"form_disable_autofill\":0,\"disable_mathjax\":0,\"enable_quick_correct_answer_info\":0,\"quick_result_correct_answer_text\":\"Correct! You have selected correct answer.\",\"quick_result_wrong_answer_text\":\"Wrong! You have selected wrong answer.\",\"quiz_processing_message\":\"\",\"quiz_limit_choice\":\"Limit of choice is reached.\",\"not_allow_after_expired_time\":0,\"scheduled_time_end\":false,\"prevent_reload\":0,\"limit_email_based_submission\":0,\"total_user_tries\":0,\"is_logged_in\":false,\"error_messages\":{\"email_error_text\":\"Not a valid e-mail address!\",\"number_error_text\":\"This field must be a number!\",\"incorrect_error_text\":\"The entered text is not correct!\",\"empty_error_text\":\"Please complete all required fields!\",\"url_error_text\":\"The entered URL is not valid!\",\"minlength_error_text\":\"Required atleast %minlength% characters.\",\"maxlength_error_text\":\"Maximum %maxlength% characters allowed.\",\"recaptcha_error_text\":\"ReCaptcha is missing\"},\"first_page\":false,\"questions_settings\":[]}\n                    <\/script>\t\t<div class='qsm-quiz-container qsm-quiz-container-1 qmn_quiz_container mlw_qmn_quiz  quiz_theme_default  '>\n\t\t\t\t\t\t\t\t<form name=\"quizForm1\" id=\"quizForm1\" action=\"\/it\/wp-json\/wp\/v2\/posts\/28617\" method=\"POST\" class=\"qsm-quiz-form qmn_quiz_form mlw_quiz_form\" novalidate enctype=\"multipart\/form-data\">\n\t\t\t\t<input type=\"hidden\" name=\"qsm_hidden_questions\" id=\"qsm_hidden_questions\" value=\"\">\n\t\t\t\t<input type=\"hidden\" name=\"qsm_nonce\" id=\"qsm_nonce_1\" value=\"29b823df61\">\n\t\t\t\t<input type=\"hidden\" name=\"qsm_unique_key\" id=\"qsm_unique_key_1\" value=\"6a069d9b5a1e0\">\n\t\t\t\t<div id=\"mlw_error_message\" class=\"qsm-error-message qmn_error_message_section\"><\/div>\n\t\t\t\t<span id=\"mlw_top_of_quiz\"><\/span>\n\t\t\t\t\t\t\t<section class=\"qsm-page \">\n\t\t\t\t\t\t\t\t<div class=\"quiz_section quiz_begin\">\n\t\t\t\t\t\t<div class='qsm-before-message mlw_qmn_message_before'>\n\t\t\t\t<h4>Patient description<\/h4>\n<p>Patient: Ms. S.R., a 42-year-old female<br \/>\nDiagnosis: Invasive Ductal Carcinoma of the right breast<br \/>\nClinical Stage: T2N2 (5\/15) M0 (Stage I)<br \/>\nHormone Receptor Status: ER-positive, PR-positive, HER2-negative<br \/>\nNo significant comorbidities<\/p>\n<h4>Case history<\/h4>\n<p>Ms. S.R. was diagnosed with early-stage breast cancer following a routine mammogram. She had no family history of breast cancer. After consultation with her oncologist, she opted for breast-conserving surgery (lumpectomy) to remove the tumor. The surgical margins were clear, and no lymph node involvement was detected on sentinel lymph node biopsy.<\/p>\n<h4>Physical examination results<\/h4>\n<p>Post-lumpectomy, Ms. S.R. had an unremarkable physical examination. No signs of infection or complications were observed. Her general health was good.<\/p>\n<h4>Results of pathological tests and other investigations<\/h4>\n<p>Histopathological Analysis: Invasive ductal carcinoma, Grade 2<\/p>\n<p>Hormone Receptor Status: ER-positive (90% of cells), PR-positive (80% of cells), HER2-negative<\/p>\n<p>Ki-67 Index: 20%<\/p>\n<p>Oncotype DX Score: 28 (High Risk)<\/p>\n<h4>Treatment plan<\/h4>\n<p>Based on the pathological characteristics and Oncotype DX score, the treatment plan for Ms. S.R. included:<br \/>\nAdjuvant chemotherapy with EC x 4 courses followed by weekly paclitaxel for 12 administrations<br \/>\nAdjuvant Radiation Therapy to the right breast to reduce the risk of local recurrence.<br \/>\nAdjuvant Endocrine Therapy with LH-RH analogue and exemestane for a minimum of 5 years<br \/>\nConsideration of CDK 4-6 inhibitor (abeamaciclib) as an adjuvant therapy option to further reduce the risk of recurrence, based on its proven efficacy in ER-positive breast cancer.<\/p>\n<h4>Expected outcome of the treatment plan<\/h4>\n<p>The expected outcome of this comprehensive treatment plan was to minimize the risk of recurrence and improve overall survival. With the inclusion of tamoxifen and the potential addition of palbociclib, the aim was to achieve long-term disease-free survival while maintaining Ms. S.R.'s quality of life.<\/p>\n<h4>Actual outcome<\/h4>\n<p>Ms. S.R. completed her radiation therapy without complications. She tolerated exemestane and LH-RH analogue well but experienced some menopausal symptoms, which were managed with lifestyle modifications and supportive care. After thorough discussion and considering the potential benefits and side effects, Ms. S.R. decided to add abemaciclib to her treatment regimen.<\/p>\n<p>Over the course of her follow-up appointments, Ms. S.R. showed no signs of disease recurrence. Her treatment was well-tolerated, and she reported minimal side effects from abemaciclib. Her quality of life remained high, and her oncologist continued to monitor her closely.<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"quiz_section qsm-question-wrapper question-type-0 question-section-id-1 \" data-qid=\"1\">\n\t\t\t\t\t\t<div class='mlw_qmn_new_question'>What adjuvant therapy do you recommend? <\/div>\n\t\t\t<div class='mlw_qmn_question  qsm_remove_bold' >\n\t\t<p><\/p>\n\t<\/div>\n\t\t<fieldset>\n\t\t<legend><\/legend>\n\t<div class='qmn_radio_answers '>\n\t\t\t\t\t\t\t\t<div class=\"qmn_mc_answer_wrap  mrq_checkbox_class\" id=\"question1-1 \">\n\t\t\t\t\t\t\t\t\t\t\t<input type='radio' class='qmn_quiz_radio qmn-multiple-choice-input ' name=\"question1\" id=\"question1_1\" value=\"0\" \/>\n\t\t\t\t\t<label class=\"qsm-input-label\" for=\"question1_1\">\n\t\t\t\t\tChemotherapy, radiation therapy, LH-RH analogue and AI for 7 to 10 years plus abemaciclib for 2 years\t\t\t\t\t<\/label>\n\t\t\t\t\t \t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<div class=\"qmn_mc_answer_wrap  mrq_checkbox_class\" id=\"question1-2 \">\n\t\t\t\t\t\t\t\t\t\t\t<input type='radio' class='qmn_quiz_radio qmn-multiple-choice-input ' name=\"question1\" id=\"question1_2\" value=\"1\" \/>\n\t\t\t\t\t<label class=\"qsm-input-label\" for=\"question1_2\">\n\t\t\t\t\tAI followed by tamoxifen to complete 7 to 10 years\t\t\t\t\t<\/label>\n\t\t\t\t\t \t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<div class=\"qmn_mc_answer_wrap  mrq_checkbox_class\" id=\"question1-3 \">\n\t\t\t\t\t\t\t\t\t\t\t<input type='radio' class='qmn_quiz_radio qmn-multiple-choice-input ' name=\"question1\" id=\"question1_3\" value=\"2\" \/>\n\t\t\t\t\t<label class=\"qsm-input-label\" for=\"question1_3\">\n\t\t\t\t\tEndocrine therapy + abemaciclib\t\t\t\t\t<\/label>\n\t\t\t\t\t \t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<div class=\"qmn_mc_answer_wrap  mrq_checkbox_class\" id=\"question1-4 \">\n\t\t\t\t\t\t\t\t\t\t\t<input type='radio' class='qmn_quiz_radio qmn-multiple-choice-input ' name=\"question1\" id=\"question1_4\" value=\"3\" \/>\n\t\t\t\t\t<label class=\"qsm-input-label\" for=\"question1_4\">\n\t\t\t\t\tTamoxifen for \u2265 5 years\t\t\t\t\t<\/label>\n\t\t\t\t\t \t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<div class=\"qmn_mc_answer_wrap  mrq_checkbox_class\" id=\"question1-5 \">\n\t\t\t\t\t\t\t\t\t\t\t<input type='radio' class='qmn_quiz_radio qmn-multiple-choice-input ' name=\"question1\" id=\"question1_5\" value=\"4\" \/>\n\t\t\t\t\t<label class=\"qsm-input-label\" for=\"question1_5\">\n\t\t\t\t\tTamoxifen followed by AI to complete 7 to 10 years\t\t\t\t\t<\/label>\n\t\t\t\t\t \t\t\t\t<\/div>\n\t\t\t\t\t \t\t\t<label style=\"display: none !important;\" for=\"question1_none\">None<\/label>\n\t\t\t<input type=\"radio\" style=\"display: none;\" name=\"question1\" id=\"question1_none\" checked=\"checked\" value=\"\" \/>\n\t\t\t\t<\/div>\n\t<\/fieldset>\n\t<input type=\"hidden\" name=\"answer_limit_keys_1\" value=\"\" \/>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/section>\n\t\t\t\t\t<input type=\"hidden\" name=\"qmn_question_list\" value=\"1Q\" \/>\n\t\t\t\t\t\t\t<div id=\"mlw_error_message_bottom\" class=\"qsm-error-message qmn_error_message_section\"><\/div>\n\t\t\t\t\t<input type=\"hidden\" name=\"qmn_all_questions_count\" id=\"qmn_all_questions_count\" value=\"1\" \/>\n\t\t\t\t\t<input type=\"hidden\" name=\"total_questions\" id=\"total_questions\" value=\"1\" \/>\n\t\t\t\t\t<input type=\"hidden\" name=\"timer\" id=\"timer\" value=\"0\" \/>\n\t\t\t\t\t<input type=\"hidden\" name=\"timer_ms\" id=\"timer_ms\" value=\"0\"\/>\n\t\t\t\t\t<input type=\"hidden\" class=\"qmn_quiz_id\" name=\"qmn_quiz_id\" id=\"qmn_quiz_id\" value=\"1\" \/>\n\t\t\t\t\t<input type='hidden' name='complete_quiz' value='confirmation' \/>\n\t\t\t\t\t\t\t\t\t<\/form>\n\t\t\t\t\t\t<\/div>\n\t\t<div style=\"display: none;\" class=\"qsm-popup qsm-popup-slide\" id=\"modal-4\" aria-hidden=\"false\"><div class=\"qsm-popup__overlay\" tabindex=\"-1\" data-micromodal-close=\"\"><div class=\"qsm-popup__container qmn_quiz_container\" role=\"dialog\" aria-modal=\"true\"><div class=\"qsm-popup__content\"><img decoding=\"async\" src=\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/plugins\/quiz-master-next\/assets\/clock.png\" alt=\"clock.png\"\/><p class=\"qsm-time-up-text\"> Time's up<\/p><\/div><footer class=\"qsm-popup__footer\"><button class=\"qsm-popup-secondary-button qmn_btn\" data-micromodal-close=\"\" aria-label=\"Close this dialog window\" onclick=\"location.reload();\">Cancel<\/button><\/footer><\/div><\/div><\/div>\n\t\t\t\t\t\t\t\t\t\t<a class=\"uabb-ss-grid-button-link\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fbreastcancer.knowledgehub.wiley.com%2Fit%2F%3Fp%3D28617%26fl_builder\" target=\"_blank\" onclick=\"window.open(this.href,'social-share','left=20,top=20,width=500,height=500,toolbar=1,resizable=0');return false;\" rel=\"noopener\">\n\t\t\t\t\t\t\t\tFacebook\n\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t<a class=\"uabb-ss-grid-button-link\" href=\"https:\/\/twitter.com\/share?url=https%3A%2F%2Fbreastcancer.knowledgehub.wiley.com%2Fit%2F%3Fp%3D28617%26fl_builder\" target=\"_blank\" onclick=\"window.open(this.href,'social-share','left=20,top=20,width=500,height=500,toolbar=1,resizable=0');return false;\" rel=\"noopener\">\n\t\t\t\t\t\t\t\tTwitter\n\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t<a class=\"uabb-ss-grid-button-link\" href=\"https:\/\/www.linkedin.com\/shareArticle?url=https%3A%2F%2Fbreastcancer.knowledgehub.wiley.com%2Fit%2F%3Fp%3D28617%26fl_builder\" target=\"_blank\" onclick=\"window.open(this.href,'social-share','left=20,top=20,width=500,height=500,toolbar=1,resizable=0');return false;\" rel=\"noopener\">\n\t\t\t\t\t\t\t\tLinkedin\n\t\t\t\t\t\t\t\t\t\t<\/a>\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":10,"featured_media":28236,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[121],"tags":[167],"class_list":["post-28617","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-commenti-dei-key-opinion-leader","tag-caso-di-studio"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Potenziale cinico degli inibitori delle CDK4\/6 nel tumore del senoProf. Giuseppe Curigliano - Risorse sul Tumore del seno per i professionisti della Salute<\/title>\n<meta name=\"description\" content=\"In questo caso di studio, il Prof. Giuseppe Curigliano discute il potenziale clinico degli inibitori delle CDK4\/6 nel tumore del seno.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Potenziale cinico degli inibitori delle CDK4\/6 nel tumore del senoProf. Giuseppe Curigliano - Risorse sul Tumore del seno per i professionisti della Salute\" \/>\n<meta property=\"og:description\" content=\"In questo caso di studio, il Prof. Giuseppe Curigliano discute il potenziale clinico degli inibitori delle CDK4\/6 nel tumore del seno.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/\" \/>\n<meta property=\"og:site_name\" content=\"Risorse sul Tumore del seno per i professionisti della Salute\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-18T10:56:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-22T14:57:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/10\/Giuseppe-Curigliano-Case-Study.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"500\" \/>\n\t<meta property=\"og:image:height\" content=\"281\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Mike Echalaz\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mike Echalaz\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/\"},\"author\":{\"name\":\"Mike Echalaz\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#\/schema\/person\/f6185d30d46da842fcbb08771556782c\"},\"headline\":\"Potenziale cinico degli inibitori delle CDK4\/6 nel tumore del seno Prof. Giuseppe Curigliano\",\"datePublished\":\"2023-10-18T10:56:50+00:00\",\"dateModified\":\"2024-01-22T14:57:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/\"},\"wordCount\":46,\"publisher\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#organization\"},\"image\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/10\/Giuseppe-Curigliano-Case-Study.jpg\",\"keywords\":[\"Caso di Studio\"],\"articleSection\":[\"Comment dei Key Opinion Leader\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/\",\"url\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/\",\"name\":\"Potenziale cinico degli inibitori delle CDK4\/6 nel tumore del seno Prof. Giuseppe Curigliano - Risorse sul Tumore del seno per i professionisti della Salute\",\"isPartOf\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/10\/Giuseppe-Curigliano-Case-Study.jpg\",\"datePublished\":\"2023-10-18T10:56:50+00:00\",\"dateModified\":\"2024-01-22T14:57:27+00:00\",\"description\":\"In questo caso di studio, il Prof. Giuseppe Curigliano discute il potenziale clinico degli inibitori delle CDK4\/6 nel tumore del seno.\",\"breadcrumb\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/#primaryimage\",\"url\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/10\/Giuseppe-Curigliano-Case-Study.jpg\",\"contentUrl\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/10\/Giuseppe-Curigliano-Case-Study.jpg\",\"width\":500,\"height\":281,\"caption\":\"Giuseppe Curigliano Case Study\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Potenziale cinico degli inibitori delle CDK4\/6 nel tumore del senoProf. Giuseppe Curigliano\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#website\",\"url\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/\",\"name\":\"Risorse sul Tumore del seno per i professionisti della Salute\",\"description\":\"Breast Cancer focused knowledge hub of resources, webinars, latest research and clinical updates for health care professionals who are treating patients living with Breast Cancer\",\"publisher\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#organization\",\"name\":\"Wiley\",\"url\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/02\/Wiley_Logo.jpg\",\"contentUrl\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/02\/Wiley_Logo.jpg\",\"width\":696,\"height\":696,\"caption\":\"Wiley\"},\"image\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#\/schema\/person\/f6185d30d46da842fcbb08771556782c\",\"name\":\"Mike Echalaz\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Potenziale cinico degli inibitori delle CDK4\/6 nel tumore del senoProf. Giuseppe Curigliano - Risorse sul Tumore del seno per i professionisti della Salute","description":"In questo caso di studio, il Prof. Giuseppe Curigliano discute il potenziale clinico degli inibitori delle CDK4\/6 nel tumore del seno.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/","og_locale":"it_IT","og_type":"article","og_title":"Potenziale cinico degli inibitori delle CDK4\/6 nel tumore del senoProf. Giuseppe Curigliano - Risorse sul Tumore del seno per i professionisti della Salute","og_description":"In questo caso di studio, il Prof. Giuseppe Curigliano discute il potenziale clinico degli inibitori delle CDK4\/6 nel tumore del seno.","og_url":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/","og_site_name":"Risorse sul Tumore del seno per i professionisti della Salute","article_published_time":"2023-10-18T10:56:50+00:00","article_modified_time":"2024-01-22T14:57:27+00:00","og_image":[{"width":500,"height":281,"url":"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/10\/Giuseppe-Curigliano-Case-Study.jpg","type":"image\/jpeg"}],"author":"Mike Echalaz","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Mike Echalaz"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/#article","isPartOf":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/"},"author":{"name":"Mike Echalaz","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#\/schema\/person\/f6185d30d46da842fcbb08771556782c"},"headline":"Potenziale cinico degli inibitori delle CDK4\/6 nel tumore del seno Prof. Giuseppe Curigliano","datePublished":"2023-10-18T10:56:50+00:00","dateModified":"2024-01-22T14:57:27+00:00","mainEntityOfPage":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/"},"wordCount":46,"publisher":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#organization"},"image":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/#primaryimage"},"thumbnailUrl":"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/10\/Giuseppe-Curigliano-Case-Study.jpg","keywords":["Caso di Studio"],"articleSection":["Comment dei Key Opinion Leader"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/","url":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/","name":"Potenziale cinico degli inibitori delle CDK4\/6 nel tumore del seno Prof. Giuseppe Curigliano - Risorse sul Tumore del seno per i professionisti della Salute","isPartOf":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/#primaryimage"},"image":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/#primaryimage"},"thumbnailUrl":"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/10\/Giuseppe-Curigliano-Case-Study.jpg","datePublished":"2023-10-18T10:56:50+00:00","dateModified":"2024-01-22T14:57:27+00:00","description":"In questo caso di studio, il Prof. Giuseppe Curigliano discute il potenziale clinico degli inibitori delle CDK4\/6 nel tumore del seno.","breadcrumb":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/#primaryimage","url":"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/10\/Giuseppe-Curigliano-Case-Study.jpg","contentUrl":"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/10\/Giuseppe-Curigliano-Case-Study.jpg","width":500,"height":281,"caption":"Giuseppe Curigliano Case Study"},{"@type":"BreadcrumbList","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/commenti-dei-key-opinion-leader\/caso-di-studio-giuseppe-curigliano\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/"},{"@type":"ListItem","position":2,"name":"Potenziale cinico degli inibitori delle CDK4\/6 nel tumore del senoProf. Giuseppe Curigliano"}]},{"@type":"WebSite","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#website","url":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/","name":"Risorse sul Tumore del seno per i professionisti della Salute","description":"Breast Cancer focused knowledge hub of resources, webinars, latest research and clinical updates for health care professionals who are treating patients living with Breast Cancer","publisher":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#organization","name":"Wiley","url":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#\/schema\/logo\/image\/","url":"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/02\/Wiley_Logo.jpg","contentUrl":"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/02\/Wiley_Logo.jpg","width":696,"height":696,"caption":"Wiley"},"image":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/#\/schema\/person\/f6185d30d46da842fcbb08771556782c","name":"Mike Echalaz"}]}},"_links":{"self":[{"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/posts\/28617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/comments?post=28617"}],"version-history":[{"count":4,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/posts\/28617\/revisions"}],"predecessor-version":[{"id":29014,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/posts\/28617\/revisions\/29014"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/media\/28236"}],"wp:attachment":[{"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/media?parent=28617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/categories?post=28617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/it\/wp-json\/wp\/v2\/tags?post=28617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}